Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma

Published:2005-04 Issue:2 Volume:24 Page:147-152
ISSN:0277-1691
Container-title:International Journal of Gynecological Pathology
language:en
Short-container-title:International Journal of Gynecological Pathology

Author:

Lee Cheng-Han,Huntsman David G,Cheang Maggie C. U,Parker Robin L,Brown Lindsay,Hoskins Paul,Miller Dianne,Gilks C Blake

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynaecology,Pathology and Forensic Medicine

Reference25 articles.

1. Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

2. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group

3. HER-2/neu expression in ovarian clear cell carcinomas

4. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma;Virchows Archiv;2023-09-07

2. A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers;Onco;2023-05-26

3. CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity;Heliyon;2023-01

4. Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling;Biochemical and Biophysical Research Communications;2022-12

5. Overexpression of HER2/HER3 and clinical feature of ovarian cancer;Journal of Gynecologic Oncology;2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3